Review of safety and efficacy with adalimumab in patients with active ankylosing spondylitis – An open-label study to evaluate the response to adalimumab in patients who have failed standard therapy or TNF [tumour necrosis factor]-alpha inhibitors (RHAPSODY)

Trial Profile

Review of safety and efficacy with adalimumab in patients with active ankylosing spondylitis – An open-label study to evaluate the response to adalimumab in patients who have failed standard therapy or TNF [tumour necrosis factor]-alpha inhibitors (RHAPSODY)

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2014

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RHAPSODY
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 04 Oct 2007 Status changed from in progress to completed.
    • 24 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top